BioGaia Past Earnings Performance
Past criteria checks 3/6
BioGaia has been growing earnings at an average annual rate of 19.4%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 14.7% per year. BioGaia's return on equity is 20.8%, and it has net margins of 24.8%.
Key information
19.4%
Earnings growth rate
16.1%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 14.7% |
Return on equity | 20.8% |
Net Margin | 24.8% |
Next Earnings Update | 12 Feb 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How BioGaia makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 1,356 | 337 | 438 | 101 |
30 Jun 24 | 1,369 | 402 | 430 | 101 |
31 Mar 24 | 1,300 | 371 | 415 | 113 |
31 Dec 23 | 1,297 | 365 | 403 | 107 |
30 Sep 23 | 1,273 | 437 | 397 | 110 |
30 Jun 23 | 1,213 | 415 | 385 | 111 |
31 Mar 23 | 1,186 | 413 | 375 | 101 |
31 Dec 22 | 1,104 | 374 | 361 | 107 |
30 Sep 22 | 1,036 | 273 | 341 | 106 |
30 Jun 22 | 952 | 246 | 302 | 103 |
31 Mar 22 | 867 | 222 | 262 | 103 |
31 Dec 21 | 785 | 196 | 231 | 105 |
30 Sep 21 | 767 | 196 | 206 | 105 |
30 Jun 21 | 725 | 164 | 198 | 105 |
31 Mar 21 | 766 | 188 | 197 | 104 |
31 Dec 20 | 747 | 180 | 198 | 105 |
30 Sep 20 | 767 | 194 | 203 | 99 |
30 Jun 20 | 802 | 211 | 210 | 105 |
31 Mar 20 | 780 | 193 | 213 | 106 |
31 Dec 19 | 768 | 187 | 209 | 105 |
30 Sep 19 | 770 | 192 | 200 | 111 |
30 Jun 19 | 778 | 205 | 195 | 110 |
31 Mar 19 | 756 | 207 | 192 | 107 |
31 Dec 18 | 742 | 215 | 181 | 100 |
30 Sep 18 | 702 | 206 | 173 | 94 |
30 Jun 18 | 675 | 197 | 166 | 86 |
31 Mar 18 | 631 | 181 | 153 | 78 |
31 Dec 17 | 615 | 181 | 149 | 76 |
30 Sep 17 | 584 | 179 | 143 | 70 |
30 Jun 17 | 562 | 172 | 139 | 69 |
31 Mar 17 | 542 | 163 | 132 | 67 |
31 Dec 16 | 535 | 160 | 129 | 64 |
30 Sep 16 | 500 | 138 | 118 | 57 |
30 Jun 16 | 480 | 129 | 114 | 53 |
31 Mar 16 | 478 | 130 | 111 | 52 |
31 Dec 15 | 483 | 138 | 112 | 53 |
30 Sep 15 | 500 | 130 | 115 | 60 |
30 Jun 15 | 474 | 119 | 114 | 59 |
31 Mar 15 | 432 | 97 | 115 | 58 |
31 Dec 14 | 482 | 147 | 107 | 54 |
30 Sep 14 | 451 | 146 | 102 | 46 |
30 Jun 14 | 433 | 145 | 98 | 43 |
31 Mar 14 | 426 | 142 | 93 | 42 |
31 Dec 13 | 316 | 62 | 94 | 41 |
Quality Earnings: BGLA.F has high quality earnings.
Growing Profit Margin: BGLA.F's current net profit margins (24.8%) are lower than last year (34.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BGLA.F's earnings have grown by 19.4% per year over the past 5 years.
Accelerating Growth: BGLA.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: BGLA.F had negative earnings growth (-23%) over the past year, making it difficult to compare to the Biotechs industry average (16.6%).
Return on Equity
High ROE: BGLA.F's Return on Equity (20.8%) is considered high.